Anticoagulation monitoring during pediatric extracorporeal membrane oxygenation

ASAIO Journal

Volumn 59, Issue 1, 2013, Pages 63-68

  Bembea, Melania M ^a,b,c   Schwartz, Jamie M ^a,b,c   Shah, Nilay ^b,c   Colantuoni, Elizabeth ^b,c   Lehmann, Christoph U ^b,c   Kickler, Thomas ^a,c   Pronovost, Peter ^a,c   Strouse, John J ^b,c  

^a Department of Anesthesiology and Critical Care ^*  (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

anticoagulation; antithrombin; ECMO; extracorporeal membrane oxygenation; heparin assay

Indexed keywords

ACTIVATED CLOTTING TIME; AGE DIFFERENCES; ANTI-COAGULATION; ANTITHROMBIN; BLOOD SAMPLES; ECMO; EXTRACORPOREAL MEMBRANE OXYGENATION; FACTOR VIII; OBSERVATIONAL STUDY;

ASSAYS; COAGULATION; INTENSIVE CARE UNITS; PEDIATRICS; RESPIRATORY THERAPY;

POLYSACCHARIDES;

ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A ANTIBODY; BLOOD CLOTTING FACTOR 8; D DIMER; HEMOGLOBIN; HEPARIN; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A;

AGE DISTRIBUTION; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING TIME; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; CRYOPRECIPITATE; EXTRACORPOREAL OXYGENATION; FIBRINOGEN BLOOD LEVEL; HEART FAILURE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFANT; INFUSION RATE; INTENSIVE CARE UNIT; MALE; NEWBORN; OBSERVATIONAL STUDY; PARTIAL THROMBOPLASTIN TIME; PRESCHOOL CHILD; PROSPECTIVE STUDY; PROTHROMBIN TIME; RESPIRATORY FAILURE; SCHOOL CHILD; SEPSIS; THROMBOCYTE COUNT; ADOLESCENT; AGE; BLEEDING; BLOOD; COHORT ANALYSIS; DRUG ANTAGONISM; DRUG MONITORING; FEMALE; METABOLISM; THROMBOSIS;

ADOLESCENT; AGE FACTORS; ANTICOAGULANTS; ANTITHROMBINS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DRUG MONITORING; EXTRACORPOREAL MEMBRANE OXYGENATION; FACTOR VIII; FACTOR XA; FEMALE; HEMORRHAGE; HEPARIN; HUMANS; INFANT; INFANT, NEWBORN; MALE; PARTIAL THROMBOPLASTIN TIME; PROSPECTIVE STUDIES; THROMBOSIS; WHOLE BLOOD COAGULATION TIME;

EID: 84872194827     PISSN: 10582916     EISSN: 1538943X     Source Type: Journal    
DOI: 10.1097/MAT.0b013e318279854a     Document Type: Article

References (19)

1. Conrad SA, Rycus PT, Dalton H: Extracorporeal Life Support Registry Report 2004. ASAIO J 51: 4-10, 2005. (Pubitemid 40165243)
2. Haines NM, Rycus PT, Zwischenberger JB, Bartlett RH, Undar A. Extracorporeal life support registry report 2008: Neonatal and pediatric cardiac cases. ASAIO J 55(1): 111-116, 2009. doi: 10.1097/MAT.0-013-318190-6-7.
3. Lawson DS, Lawson AF, Walczak R, et al: North American neona¬tal extracorporeal membrane oxygenation (ECMO) devices and team roles: 2008 survey results of Extracorporeal Life Support Organization (ELSO) centers. J Extra Corpor Technol 40: 166-174, 2008.
4. Nankervis CA, Preston TJ, Dysart KC, et al: Assessing heparin dos¬ing in neonates on venoarterial extracorporeal membrane oxy¬genation. ASAIO J 53: 111-114, 2007. (Pubitemid 46145500)
5. Urlesberger B, Zobel G, Zenz W, et al: Activation of the clotting system during extracorporeal membrane oxygenation in term newborn infants. J Pediatr 129: 264-268, 1996. (Pubitemid 27483799)
6. Muntean W: Coagulation and anticoagulation in extracorporeal membrane oxygenation. Artif Organs 23: 979-983, 1999.
7. Khaja WA, Bilen O, Lukner RB, Edwards R, Teruya J: Evaluation of heparin assay for coagulation management in newborns under¬going ECMO. Am J Clin Pathol 134: 950-954, 2010.
8. Ignjatovic V, Lai C, Summerhayes R, et al: Age-related differences in plasma proteins: How plasma proteins change from neonates to adults. PLoS ONE 6: E17213, 2011.
9. Monagle P, Barnes C, Ignjatovic V, et al: Developmental haemostasis. Impact for clinical haemostasis laboratories. Thromb Haemost 95: 362-372, 2006.
10. Agati S, Ciccarello G, Salvo D, Turla G, Undar A, Mignosa C: Use of a novel anticoagulation strategy during ECMO in a pediatric population: Single-center experience. ASAIO J 52: 513-516, 2006. (Pubitemid 44394258)
11. Oliver WC: Anticoagulation and coagulation management for ECMO. Semin Cardiothorac Vasc Anesth 13: 154-175, 2009.
12. Sievert A, Uber W, Laws S, Cochran J: Improvement in long-term ECMO by detailed monitoring of anticoagulation: A case report. Perfusion 26: 59-64, 2011.
13. Arnold P, Jackson S, Wallis J, Smith J, Bolton D, Haynes S: Coagulation factor activity during neonatal extra-corporeal membrane oxy¬genation. Intensive Care Med 27: 1395-1400, 2001. (Pubitemid 32758938)
14. McDonald MM, Jacobson LJ, Hay WW Jr, Hathaway WE: Heparin clearance in the newborn. Pediatr Res 15: 1015-1018, 1981. (Pubitemid 11087048)
15. Perry DJ, Fitzmaurice DA, Kitchen S, Mackie IJ, Mallett S: Point-of-care testing in haemostasis. Br J Haematol 150: 501-514, 2010.
16. Fleming GM, Gupta M, Cooley E, Remenapp R, Bartlett RH, Annich GM: Maintaining the standard: A quality assurance study for new equipment in the Michigan ECMO Program. ASAIO J 53: 556-560, 2007. (Pubitemid 47462249)
17. Colby CE, Sheehan A, Benitz W, Van Meurs K, Halamek LP, Moss RL: Maintaining adequate anticoagulation on extracorpo¬real membrane oxygenation therapy: Hemochron Junior Low Range versus Hemochron 400. J Extra Corpor Technol 35: 35-38, 2003. (Pubitemid 36337277)
18. Levine MN, Hirsh J, Gent M, et al: A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 154: 49-56, 1994. (Pubitemid 24018101)
19. Olson JD, Arkin CF, Brandt JT, et al: College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: Laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med 122: 782-798, 1998.